ABSORB STEMI: the TROFI II Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 191 participants.

Also called NCT01986803

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 191 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as a collaborator
  • ECRI bv Registry lists this organization as the lead sponsor
  • Terumo Europe N.V. Registry lists this organization as a collaborator
Registry
  • NCT NCT01986803
Other papers using this trial's data
  • Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy JACC. Cardiovascular interventions, 2017-09-25 DOI, PubMed 28935079

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Denmark, Netherlands, Spain, Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01986803. Randomized; single masking; primary purpose treatment. Start 2014-01-06 (actual); primary completion 2015-04-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ABSORB STEMI: the TROFI II Study
Condition
Acute ST Segment Elevation Myocardial Infarction
Lead sponsor
ECRI bv (class: industry)
Collaborator
Abbott Medical Devices (class: industry)
Collaborator
Terumo Europe N.V. (class: industry)

Record details

Record id
cardio:ct-nct01986803
Content hash
531bd9d9fd9923b59d9ee09943ec064a262b21b7be5ec05b50951ef27e27a6bf